Noninvasive imaging of cell-mediated therapy for treatment of cancer

Journal of Nuclear Medicine

Volumn 49, Issue SUPPL.6, 2008, Pages

  Akins, Elizabeth J ^a   Dubey, Purnima ^a  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

Cancer; Cell mediated therapy; Imaging; Noninvasive imaging

Indexed keywords

3 (2 FLUOROETHYL)SPIPERONE F 18; 8 QUINOLINOL INDIUM IN 111; CONTRAST MEDIUM; DOPAMINE 2 RECEPTOR; FLUORESCENT DYE; FLUOROCLEBOPRIDE F 18; FLUORODEOXYGLUCOSE F 18; GANCICLOVIR; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; IMMUNOMODULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 2; IODINE 124; N SUCCINIMIDYL 4 FLUOROBENZOATE F 18; PERFLUORO COMPOUND; PYRUVALDEHYDE BIS(N 4 METHYLTHIOSEMICARBAZONE) CU 64; RADIOISOTOPE; RENILLA LUCIFERIN 2 MONOOXYGENASE; RETROVIRUS VECTOR; SODIUM IODIDE SYMPORTER; SUPERPARAMAGNETIC IRON OXIDE; TECHNETIUM 99M; TRACER;

ACTIVE IMMUNIZATION; ADJUVANT THERAPY; ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASE; CANCER CELL; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LABELING; CELL THERAPY; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CHRONIC INFLAMMATION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; EFFECTOR CELL; GENE TARGETING; GRAFT VERSUS HOST REACTION; HUMAN; IMAGING SYSTEM; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MOLECULAR IMAGING; NATURAL KILLER T CELL; NEOPLASM; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PASSIVE IMMUNIZATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REPORTER GENE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THREE DIMENSIONAL IMAGING;

ADOPTIVE TRANSFER; ANIMALS; ANTIGEN PRESENTATION; CELL COUNT; DENDRITIC CELLS; GENES, REPORTER; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ACTIVE; LUMINESCENT MEASUREMENTS; LYMPHOCYTES; MAGNETIC RESONANCE IMAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; WHOLE BODY IMAGING;

EID: 46749093827     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.045971     Document Type: Review

References (129)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
2. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329-360.
3. Paul WE, ed. Fundamental Immunology. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2003.
4. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.
5. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA. 2002;99:16168-16173.
6. Ljunggren HG, Malmberg KJ. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol. 2007;7:329-339.
7. Yamaguchi T, Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol. 2006;16:115-123.
8. Mapara MY, Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol. 2004;22:1136-1151.
9. Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev. 2004;199:251-263.
10. Gross G, Margalit A. Targeting tumor-associated antigens to the MHC class I presentation pathway. Endocr Metab Immune Disord Drug Targets. 2007;7:99-109.
11. Liu MA, Wahren B, Karlsson Hedestam GB. DNA vaccines: recent developments and future possibilities. Hum Gene Ther. 2006;17:1051-1061.
12. Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med. 2007;13:108-116.
13. Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol. 2003;195:346-355.
14. Hogquist KA, Baldwin TA, Jameson SC. Central tolerance: learning self-control in the thymus. Nat Rev Immunol. 2005;5:772-782.
15. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol. 2001;2:293-299.
16. Hodi FS, Dranoff G. Combinatorial cancer immunotherapy. Adv Immunol. 2006;90:341-368.
17. Mosca PJ, Clay TM, Morse MA, Lyerly HK. Immune monitoring. Cancer Treat Res. 2005;123:369-388.
18. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2003;17:545-580.
19. Halin C, Rodrigo Mora J, Sumen C, von Andrian UH. In vivo imaging of lymphocyte trafficking. Annu Rev Cell Dev Biol. 2005;21:581-603.
20. Gilad AA, Winnard PT Jr, van Zijl PC, Bulte JW. Developing MR reporter genes: promises and pitfalls. NMR Biomed. 2007;20:275-290.
21. 111In-oxine labelled granulocytes in man: first clinical results. Nucl Med Commun. 1988;9:435-447.
22. Schafer E, Dummer R, Eilles C, et al. Imaging pattern of radiolabelled lymphokine-activated killer cells in patients with metastatic malignant melanoma. Eur J Nucl Med. 1991;18:106-110.
23. Beeres SL, Bengel FM, Bartunek J, et al. Role of imaging in cardiac stem cell therapy. J Am Coll Cardiol. 2007;49:1137-1148.
24. 4-methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography. Proc Natl Acad Sci USA. 2002;99:3030-3035.
25. Ahrens ET, Flores R, Xu H, Morel PA. In vivo imaging platform for tracking immunotherapeutic cells. Nat Biotechnol. 2005;23:983-987.
26. Baumjohann D, Hess A, Budinsky L, Brune K, Schuler G, Lutz MB. In vivo magnetic resonance imaging of dendritic cell migration into the draining lymph nodes of mice. Eur J Immunol. 2006;36:2544-2555.
27. de Vries IJ, Lesterhuis WJ, Barentsz JO, et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol. 2005;23:1407-1413.
28. Verdijk P, Scheenen TW, Lesterhuis WJ, et al. Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines. Int J Cancer. 2007;120:978-984.
29. Agger R, Petersen MS, Petersen CC, et al. T cell homing to tumors detected by 3D-coordinated positron emission tomography and magnetic resonance imaging. J Immunother. 2007;30:29-39.
30. Smirnov P, Lavergne E, Gazeau F, et al. In vivo cellular imaging of lymphocyte trafficking by MRI: a tumor model approach to cell-based anticancer therapy. Magn Reson Med. 2006;56:498-508.
31. Kircher MF, Allport JR, Graves EE, et al. In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors. Cancer Res. 2003;63:6838-6846.
32. Amsalem Y, Mardor Y, Feinberg MS, et al. Iron-oxide labeling and outcome of transplanted mesenchymal stem cells in the infarcted myocardium. Circulation. 2007;116(11, suppl):I38-I45.
33. Hill JM, Dick AJ, Raman VK, et al. Serial cardiac magnetic resonance imaging of injected mesenchymal stem cells. Circulation. 2003;108:1009-1014.
34. 18F]fluorodeoxyglucose labelling and retention for in vivo positron emission tomography imaging of monocyte trafficking. Nucl Med Commun. 2002;23:551-557.
35. Rao J, Dragulescu-Andrasi A, Yao H. Fluorescence imaging in vivo: recent advances. Curr Opin Biotechnol. 2007;18:17-25.
36. Swirski FK, Berger CR, Figueiredo JL, et al. A near-infrared cell tracker reagent for multiscopic in vivo imaging and quantification of leukocyte immune responses. PLoS ONE. 2007;2:e1075.
37. Chudakov DM, Lukyanov S, Lukyanov KA. Fluorescent proteins as a toolkit for in vivo imaging. Trends Biotechnol. 2005;23:605-613.
38. Blasberg RG, Tjuvajev JG. Molecular-genetic imaging: current and future perspectives. J Clin Invest. 2003;111:1620-1629.
39. Greer LF III, Szalay AA. Imaging of light emission from the expression of luciferases in living cells and organisms: a review. Luminescence. 2002;17:43-74.
40. Lindqvist C, Karp M, Akerman K, Oker-Blom C. Flow cytometric analysis of bioluminescence emitted by recombinant baculovirus-infected insect cells. Cytometry. 1994;15:207-212.
41. 18F-FEAU as a radiotracer for herpes simplex virus thymidine kinase gene expression: in-vitro comparison with other PET tracers. Nucl Med Commun. 2006;27:25-30.
42. 18F tracers for the investigation of brain functions. Acta Radiol Suppl. 1990;374:37-41.
43. Nader MA, Czoty PW. PET imaging of dopamine D2 receptors in monkey models of cocaine abuse: genetic predisposition versus environmental modulation. Am J Psychiatry. 2005;162:1473-1482.
44. 18F](+)-4-fluorobenzyltrozamicol: in vitro binding studies and positron emission tomography studies in nonhuman primates. Synapse. 1997;25:368-380.
45. Dadachova E, Carrasco N. The Na/I symporter (NIS): imaging and therapeutic applications. Semin Nucl Med. 2004;34:23-31.
46. Barquinero J, Eixarch H, Perez-Melgosa M. Retroviral vectors: new applications for an old tool. Gene Ther. 2004;11(suppl 1):S3-S9.
47. Breckpot K, Aerts JL, Thielemans K. Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Ther. 2007;14:847-862.
48. Hanazono Y, Brown KE, Dunbar CE. Primary T lymphocytes as targets for gene therapy. J Hematother Stem Cell Res. 2000;9:611-620.
49. Jahner D, Stuhlmann H, Stewart CL, et al. De novo methylation and expression of retroviral genomes during mouse embryogenesis. Nature. 1982;298:623-628.
50. Chang AH, Sadelain M. The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the LTR, and the promise of lineage-restricted vectors. Mol Ther. 2007;15:445-456.
51. + cells using lentiviral vectors with regulatory sequences from the CD4 gene. Blood. 2003;101:3416-3423.
52. Hadjantonakis AK, Dickinson ME, Fraser SE, Papaioannou VE. Technicolour transgenics: imaging tools for functional genomics in the mouse. Nat Rev Genet. 2003;4:613-625.
53. Sinn PL, Sauter SL, McCray PB Jr. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors - design, biosafety, and production. Gene Ther. 2005;12:1089-1098.
54. Pantuck AJ, Matherly J, Zisman A, et al. Optimizing prostate cancer suicide gene therapy using herpes simplex virus thymidine kinase active site variants. Hum Gene Ther. 2002;13:777-789.
55. Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol. 2002;2:227-238.
56. Schimmelpfennig CH, Schulz S, Arber C, et al. Ex vivo expanded dendritic cells home to T-cell zones of lymphoid organs and survive in vivo after allogeneic bone marrow transplantation. Am J Pathol. 2005;167:1321-1331.
57. Olasz EB, Lang L, Seidel J, Green MV, Eckelman WC, Katz SI. Fluorine-18 labeled mouse bone marrow-derived dendritic cells can be detected in vivo by high resolution projection imaging. J Immunol Methods. 2002;260:137-148.
58. Viehl CT, Becker-Hapak M, Lewis JS, et al. A tat fusion protein-based tumor vaccine for breast cancer. Ann Surg Oncol. 2005;12:517-525.
59. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol. 2003;3:630-641.
60. 111In-oxine labelled white cell scans in the assessment of inflammatory bowel disease. Eur J Nucl Med. 1993;20:195-200.
61. Dubey P, Su H, Adonai N, et al. Quantitative imaging of the T cell antitumor response by positron-emission tomography. Proc Natl Acad Sci USA. 2003;100:1232-1237.
62. Koehne G, Doubrovin M, Doubrovina E, et al. Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. Nat Biotechnol. 2003;21:405-413.
63. -/- mice by positron-emission tomography. J Immunol. 2006;176:4459-4467.
64. Matsui K, Wang Z, McCarthy TJ, Allen PM, Reichert DE. Quantitation and visualization of tumor-specific T cells in the secondary lymphoid organs during and after tumor elimination by PET. Nucl Med Biol. 2004;31:1021-1031.
65. Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood. 2003;101:640-648.
66. Kim D, Hung CF, Wu TC. Monitoring the trafficking of adoptively transferred antigen-specific CD8-positive T cells in vivo, using noninvasive luminescence imaging. Hum Gene Ther. 2007;18:575-588.
67. Garofalakis A, Zacharakis G, Meyer H, et al. Three-dimensional in vivo imaging of green fluorescent protein-expressing T cells in mice with noncontact fluorescence molecular tomography. Mol Imaging. 2007;6:96-107.
68. Wang X, Rosol M, Ge S, et al. Dynamic tracking of human hematopoietic stem cell engraftment using in vivo bioluminescence imaging. Blood. 2003;102:3478-3482.
69. Mayer-Kuckuk P, Doubrovin M, Bidaut L, et al. Molecular imaging reveals skeletal engraftment sites of transplanted bone marrow cells. Cell Transplant. 2006;15:75-82.
70. Cao YA, Bachmann MH, Beilhack A, et al. Molecular imaging using labeled donor tissues reveals patterns of engraftment, rejection, and survival in transplantation. Transplantation. 2005;80:134-139.
71. Shu CJ, Guo S, Kim YJ, et al. Visualization of a primary anti-tumor immune response by positron emission tomography. Proc Natl Acad Sci USA. 2005;102:17412-17417.
72. Riddell SR, Berger C, Murata M, Randolph S, Warren EH. The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. Blood Rev. 2003;17:153-162.
73. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood. 2004;103:767-776.
74. + regulatory T cells in prevention of acute graft-versus-host disease. Blood. 2007;109:2225-2233.
75. Nguyen VH, Zeiser R, Dasilva DL, et al. In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. Blood. 2007;109:2649-2656.
76. Kesarwala AH, Prior JL, Sun J, Harpstrite SE, Sharma V, Piwnica-Worms D. Second-generation triple reporter for bioluminescence, micro-positron emission tomography, and fluorescence imaging. Mol Imaging. 2006;5:465-474.
77. Ponomarev V, Doubrovin M, Serganova I, et al. A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. Eur J Nucl Med Mol Imaging. 2004;31:740-751.
78. Ray P, De A, Min JJ, Tsien RY, Gambhir SS. Imaging tri-fusion multimodality reporter gene expression in living subjects. Cancer Res. 2004;64:1323-1330.
79. Ray P, Tsien R, Gambhir SS. Construction and validation of improved triple fusion reporter gene vectors for molecular imaging of living subjects. Cancer Res. 2007;67:3085-3093.
80. Ray P, Wu AM, Gambhir SS. Optical bioluminescence and positron emission tomography imaging of a novel fusion reporter gene in tumor xenografts of living mice. Cancer Res. 2003;63:1160-1165.
81. Kim YJ, Dubey P, Ray P, Gambhir SS, Witte ON. Multimodality imaging of lymphocytic migration using lentiviral-based transduction of a tri-fusion reporter gene. Mol Imaging Biol. 2004;6:331-340.
82. Radu CG, Shu CJ, Shelly SM, Phelps ME, Witte ON. Positron emission tomography with computed tomography imaging of neuroinflammation in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA. 2007;104:1937-1942.
83. Pittet MJ, Swirski FK, Reynolds F, Josephson L, Weissleder R. Labeling of immune cells for in vivo imaging using magnetofluorescent nanoparticles. Nat Protocols. 2006;1:73-79.
84. Lucas AJ, Hawkes RC, Ansorge RE, et al. Development of a combined microPET-MR system. Technol Cancer Res Treat. 2006;5:337-341.
85. Cherry SR. The 2006 Henry N. Wagner Lecture: of mice and men (and positrons) - advances in PET imaging technology. J Nucl Med. 2006;47:1735-1745.
86. O'Connor MK, Kemp BJ. Single-photon emission computed tomography/computed tomography: basic instrumentation and innovations. Semin Nucl Med. 2006;36:258-266.
87. Prout DL, Silverman RW, Chatziioannou A. Readout of the optical PET (OPET) detector. IEEE Trans Nucl Sci. 2005;52:28-32.
88. Blattman JN, Antia R, Sourdive DJ, et al. Estimating the precursor frequency of naive antigen-specific CD8 T cells. J Exp Med. 2002;195:657-664.
89. Su H, Forbes A, Gambhir SS, Braun J. Quantitation of cell number by a positron emission tomography reporter gene strategy. Mol Imaging Biol. 2004;6:139-148.
90. Contag CH, Bachmann MH. Advances in in vivo bioluminescence imaging of gene expression. Annu Rev Biomed Eng. 2002;4:235-260.
91. 131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity. Eur J Nucl Med Mol Imaging. 2006;33:988-997.
92. Nimmagadda S, Mangner TJ, Douglas KA, Muzik O, Shields AF. Biodistribution, PET, and radiation dosimetry estimates of HSV-tk gene expression imaging agent 1-(2′-deoxy-2′-β-D- arabinofuranosyl)-5-iodouracil in normal dogs. J Nucl Med. 2007;48:655-660.
93. 18F-FHBG: a reporter probe for imaging herpes simplex virus type-1 thymidine kinase reporter gene expression. J Nucl Med. 2001;42:1225-1234.
94. Hakamata Y, Murakami T, Kobayashi E. "Firefly rats" as an organ/cellular source for long-term in vivo bioluminescent imaging. Transplantation. 2006;81:1179-1184.
95. + hematopoietic cells. Blood. 2001;97:1951-1959.
96. Stripecke R, Carmen Villacres M, Skelton D, Satake N, Halene S, Kohn D. Immune response to green fluorescent protein: implications for gene therapy. Gene Ther. 1999;6:1305-1312.
97. Riddell SR, Elliott M, Lewinsohn DA, et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med. 1996;2:216-223.
98. Traversari C, Marktel S, Magnani Z, et al. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood. 2007;109:4708-4715.
99. Ponomarev V, Doubrovin M, Shavrin A, et al. A human-derived reporter gene for noninvasive imaging in humans: mitochondrial thymidine kinase type 2. J Nucl Med. 2007;48:819-826.
100. 11C-m-hydroxyephedrine as a reporter gene/reporter probe for PET of gene therapy. J Nucl Med. 2005;46:2068-2075.
101. Cohen B, Dafni H, Meir G, Harmelin A, Neeman M. Ferritin as an endogenous MRI reporter for noninvasive imaging of gene expression in C6 glioma tumors. Neoplasia. 2005;7:109-117.
102. Groot-Wassink T, Aboagye EO, Glaser M, Lemoine NR, Vassaux G. Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene. Hum Gene Ther. 2002;13:1723-1735.
103. MacLaren DC, Gambhir SS, Satyamurthy N, et al. Repetitive, non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals. Gene Ther. 1999;6:785-791.
104. Moore A, Josephson L, Bhorade RM, Basilion JP, Weissleder R. Human transferrin receptor gene as a marker gene for MR imaging. Radiology. 2001;221:244-250.
105. Rogers BE, Zinn KR, Buchsbaum DJ. Gene transfer strategies for improving radiolabeled peptide imaging and therapy. Q J Nucl Med. 2000;44: 208-223.
106. Ponomarev V, Doubrovin M, Lyddane C, et al. Imaging TCR-dependent NFATmediated T-cell activation with positron emission tomography in vivo. Neoplasia. 2001;3:480-488.
107. 2+, calcineurin, and NF-AT. Cell. 1999;96:611-614.
108. Lotze MT, Robb RJ, Sharrow SO, Frana LW, Rosenberg SA. Systemic administration of interleukin-2 in humans. J Biol Response Mod. 1984;3:475-482.
109. Chianelli M, Signore A, Fritzberg AR, Mather SJ. The development of technetium-99m-labelled interleukin-2: a new radiopharmaceutical for the in vivo detection of mononuclear cell infiltrates in immune-mediated diseases. Nucl Med Biol. 1997;24:579-586.
110. 123I-interleukin- 2: biochemical characterization and in vivo use for imaging autoimmune diseases. Nucl Med Commun. 2003;24:305-316.
111. 99mTc-HYNIC-interleukin-12, a new specific radiopharmaceutical for imaging T lymphocytes. Eur J Nucl Med Mol Imaging. 2006;33:474-482.
112. Metlay JP, Witmer-Pack MD, Agger R, Crowley MT, Lawless D, Steinman RM. The distinct leukocyte integrins of mouse spleen dendritic cells as identified with new hamster monoclonal antibodies. J Exp Med. 1990;171:1753-1771.
113. + T cells in vivo. J Immunol. 1995;154:5684-5693.
114. Kioussis D, Ellmeier W. Chromatin and CD4, CD8A and CD8B gene expression during thymic differentiation. Nat Rev Immunol. 2002;2:909-919.
115. Zheng Y, Rudensky AY. Foxp3 in control of the regulatory T cell lineage. Nat Immunol. 2007;8:457-462.
116. Mantel PY, Ouaked N, Ruckert B, et al. Molecular mechanisms underlying FOXP3 induction in human T cells. J Immunol. 2006;176:3593-3602.
117. de Boer J, Williams A, Skavdis G, et al. Transgenic mice with hematopoietic and lymphoid specific expression of Cre. Eur J Immunol. 2003;33:314-325.
118. Wan YY, Flavell RA. Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter. Proc Natl Acad Sci USA. 2005;102:5126-5131.
119. Shimizu C, Kawamoto H, Yamashita M, et al. Progression of T cell lineage restriction in the earliest subpopulation of murine adult thymus visualized by the expression of lck proximal promoter activity. Int Immunol. 2001;13:105-117.
120. Smyth MJ, Kershaw MH, Hulett MD, McKenzie IF, Trapani JA. Use of the 5′-flanking region of the mouse perforin gene to express human Fc gamma receptor I in cytotoxic T lymphocytes. J Leukoc Biol. 1994;55:514-522.
121. + T cells. Eur J Immunol. 2006;36:3146-3156.
122. Aune TM, Penix LA, Rincon MR, Flavell RA. Differential transcription directed by discrete gamma interferon promoter elements in naive and memory (effector) CD4 T cells and CD8 T cells. Mol Cell Biol. 1997;17:199-208.
123. Kumar S, Skeen MJ, Adiri Y, et al. A cytokine promoter/yellow fluorescent protein reporter transgene serves as an early activation marker of lymphocyte subsets. Cell Immunol. 2005;237:131-140.
124. Jaalouk DE, Lejeune L, Couture C, Galipeau J. A self-inactivating retrovector incorporating the IL-2 promoter for activation-induced transgene expression in genetically engineered T-cells. Virol J. 2006;3:97.
125. Venisnik KM, Olafsen T, Loening AM, Iyer M, Gambhir SS, Wu AM. Bifunctional antibody-Renilla luciferase fusion protein for in vivo optical detection of tumors. Protein Eng Des Sel. 2006;19:453-460.
126. Xu H, Baidoo K, Gunn AJ, et al. Design, synthesis, and characterization of a dual modality positron emission tomography and fluorescence imaging agent for monoclonal antibody tumor-targeted imaging. J Med Chem. 2007;50:4759-4765.
127. Pipkin ME, Ljutic B, Cruz-Guilloty F, et al. Chromosome transfer activates and delineates a locus control region for perforin. Immunity. 2007;26:29-41.
128. Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12:6106-6115.
129. 18F]FHBG PET imaging of T cell homing in patients with gliomas. AMI/SMI Joint Meeting; September 8-11, 2007; Providence, RI. Abstract 153.